Bing

SEARCH HISTORY

What is amazing is that Dendreon always was considered a buyout candidate, yet the company always acted ... and the discounted cash flow target is only a $3.00 stock. Shares closed at $2.53 on Friday, against a 52-week range of $2.23 to $7.22.
24/7 Wall ST · 10/28/2013
Many investors appear to be quite bearish on Dendreon Corporation ( DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is sold short, suggesting an extreme level of bearishness for ...
NASDAQ · 6/26/2014
Investors in Dendreon Corp (NASD: DNDN) saw new options become available today, for the September 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new September 27th …
Forbes · 9/19/2013
More from Bing News
NEW YORK (TheStreet) -- Dendreon (DNDN) surged Tuesday after the company announced data from ProACT and IMPACT studies on PROVENGE, or sipuleucel-T. The data indicated PROVENGE treatment induced an antigen spread associated with an …
The Street · 5/20/2014
Dendreon continued to watch its stock decline Wednesday, a day after the Seattle company announced it might not be able to repay a looming debt of $620 million when it comes due in early 2016. The stock (NASDAQ: DNDN) was trading at $1.37 a share …
The Business Journal · ByGreg Lamm · 8/13/2014
Shares of Dendreon are off over 2% today and down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, DNDN, currently at 34 and change, is 23 points off its high of 57.67, which it reached after the FDA approved the ...
The Wall Street Journal · ByJames Altucher · 6/24/2010
They said an investigation by the Securities and Exchange Commission into the still unexplained trading event, during which shares of Dendreon plunged more than 69 percent in 70 seconds, is ongoing. It is not clear if the SEC inquiry into the incident ...
Reuters · ByMatthew Goldstein · 3/9/2010
The Securities and Exchange Commission's insider trading team has Dendreon ($DNDN) under a microscope. The agency has launched a civil investigation into stock trades by former CEO Mitchell Gold to see whether he acted on inside information about ...
FiercePharma · ByTracy Staton · 4/30/2013
an investor, purporting to represent a class consisting of persons who purchased Dendreon common stock between April 29, 2010 and August 3, 2011, sought unspecified damages from Dendreon and three current and former officers of the Company for …
StreetInsider · 3/18/2013
Shares of Dendreon fell as much as 37 percent Tuesday after the struggling Seattle biotechnology company warned it might restructure its finances with “no guarantee that any such alternative will provide value for the company’s stockholders.”
The Seattle Times · 8/12/2014